Immuneel

Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells. It has developed CAR-T cell therapy extracted from patient's blood cells to target cancerous cells. The product pipeline includes IMN-003A, IMN-001, and IMN-002 for leukemias and lymphomas.